In patients with non-ST-elevation acute coronary syndrome, pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial.
Fuente : http://www.eurekalert.org/pub_releases/2013-09/eso...
Fuente : http://www.eurekalert.org/pub_releases/2013-09/eso...